Adaptive is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The company offers testing instruments for diagnose, treat, and monitor disease. The company serves customers in the United States.

Alector is a clinical stage biopharmaceutical company. The company is engaged in developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The company's preclinical and clinical programs include: AL001, which is the company's progranulin (PGRN) product candidate in clinical development, is designed to treat frontotemporal dementia, a severe, rapidly progressing neurodegenerative disorder: AL101, which is the company's second PGRN product candidate that is being developed for the indications, such as Alzheimer's disease and Parkinson's disease; and AL002 and AL003, which are candidate for Alzheimer's disease.

Alliance Resource Partners is a natural resource company. The company is a coal producer in the eastern United States. The company markets its coal production to main domestic and international utilities and industrial users. The company has two reportable segments: Illinois Basin, which comprises of multiple operating segments, including operating mining complexes Webster County Coal's Dotiki mining complex, Gibson County Coal's mining complex, River View's mining complex and the Hamilton mining complex; and Appalachia, which comprises of multiple operating segments, including the Mettiki mining complex, the Tunnel Ridge mining complex, the MC Mining mining complex and the Penn Ridge property.

American Oriental Bioengineering is a pharmaceutical company engaged in the development, manufacture and commercialization of a range of pharmaceutical and healthcare products. Co.'s manufacturing business consists of three main product categories, including prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Co. sells its products primarily to hospitals, clinics, pharmacies and retail outlets in all provinces, including rural areas and cities in China. Co.'s primary products include Shuanghuanglian Lyophilized Injection Powder and Cease Enuresis Soft Gel. As of Dec 31 2012, Co. marketed 109 pharmaceutical products primarily in China.

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. The company's main product candidate, AT-007, is a central nervous system, penetrant AR inhibitor (ARI) that the company is developing for the treatment of galactosemia, a rare pediatric metabolic disease that affects how the body processes a simple sugar called galactose. The company's second product candidate, AT-001, is an ARI with systemic exposure and peripheral nerve permeability that the company is developing for the treatment of diabetic cardiomyopathy, a fatal fibrosis of the heart.

Arcimoto is engaged primarily in the design, development and pre-production of three-wheeled electric vehicles. The company is developing three vehicle products based on the Arcimoto Platform: the Fun Utility Vehicle? (FUV?), the Rapid Responder?, and the Deliverator?. The company's primary product is the Fun Utility Vehicle. The FUV is a two passengers with gear, rockstar parking (three to a space). The Rapid Responder is pure-electric and designed for emergency, security and law enforcement services. The Deliverator is a pure electric, last-mile delivery solution designed to get goods where they need to go.

Boston Beer Company is an alcoholic beverage company and a craft brewer. The company is engaged in the business of selling alcohol beverages throughout the United States and in selected international markets. The company's brands include Samuel Adams?, Twisted Tea?, Truly Hard Seltzer?, Wild Leaf? Hard Tea and Tura? Alcoholic Kombucha. The company produces alcohol beverages including malt beverages, hard cider and hard seltzer at the company-owned breweries and its cidery and under contract arrangements at other brewery locations. The company sells its products mainly in the United States, but also has markets in Canada, Europe, Israel, Australia, New Zealand, the Caribbean, the Pacific Rim, Mexico, and Central and South America.

Cassava Sciences is a clinical-stage drug development company. The company focuses on developing new product candidates and to guide these through various regulatory and development pathways in preparation for their potential commercialization. The company's clinical-stage biopharmaceutical assets include: PTI-125, which is its product candidate for the treatment of Alzheimer's disease; and PTI-125Dx, which it is developing as a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company owns worldwide rights to PTI-125 and PTI-125Dx, without royalty obligations to any third party.

Castle Biosciences is a commercial-stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make treatment decisions. The company's main product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. The company also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. The company is developing additional products in treating their patients' skin cancer, such as DecisionDx-SCC.

Century Casinos is an international casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurant, horse racing and entertainment facilities. The company owns casino operations in North America and England; develops a racetrack and entertainment center (REC) in Edmonton, Canada; holds interest in casino licenses throughout Poland; holds interest in a REC in Calgary, Canada, and the pari-mutuel off-track betting network in southern Alberta, Canada; manages cruise ship-based casinos on international waters; manages a hotel, entertainment and gaming club in Vietnam through a majority-owned subsidiary, and provides gaming services in Argentina.

Codexis discovers, develops and sells proteins to its clients. The company has two segments: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications; and Novel Biotherapeutics, in which it has announced a global development, option and license agreement with Societe des Produits Nestle S.A. to develop CDX-6114, its own orally administrable enzyme therapeutic candidate for the potential treatment of phenylketonuria. The company's products include protein catalysts, chemical intermediates and Codex? biocatalyst panels and kits.

CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company's primary focus is on the development of its primary product candidate, Neutrolin?, for potential commercialization in the United States and other main markets. The company has in-licensed the worldwide rights to develop and commercialize Neutrolin. Neutrolin is an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as dialysis, critical/intensive care, and oncology.

HyreCar is a peer-to-peer car-sharing marketplace that allows car owners to rent their cars to ride-sharing service drivers. The company's business is based on car-sharing marketplace developed to: onboard Owners and Drivers; facilitate the matching of Owners and Drivers; and log rental activity for Owners and Drivers. All transactions related to the rental (including, but not limited to, background checks, rentals, deposits and insurance costs) are run through the HyreCar platform. Drivers and Owners access their rental or car dashboards through a login. Drivers can initiate, terminate or extend a rental through the platform while Owners can manage their car or fleet of cars through the platform.

Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors. The company's product candidates include: vopratelimab, which is a clinical stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in various solid tumors; JTX-4014, which is a clinical-stage anti-PD-1 antibody that the company is developing primarily for use in combination with future product candidates; and JTX-8064, which is an antibody that binds to LILRB2, a cell surface receptor expressed on macrophages.

Kopin is an inventor, developer, manufacturer and seller of components and systems for industrial, public safety and consumer augmented and virtual reality wearable headsets, soldier, avionic and military armored vehicle applications, 3D optical inspection systems and training and simulation markets. The components that the company provided for sale in consisted of its proprietary miniature active-matrix liquid crystal displays, liquid crystal on silicon displays/ Spatial Light Modulators, organic light emitting diode displays, application specific integrated circuits, backlights, optical lenses and audio integrated circuits.

Marathon Patent Group is engaged in acquiring patents and patent rights from patent holders, who range from individual inventors to Fortune 500 companies. Co.'s intellectual property is primarily comprised of issued patents, patent applications and contract rights to patents. As of Dec 31 2016, on a consolidated basis, Co.'s operating subsidiaries owned 515 patents and had economic rights to over 10,000 additional patents. Co.'s patent portfolios include subject matters related to communication and PBX equipment, network and data management, web page content translator and device-to-device transfer system, telephony and data transactions, and natural language interface.

Molecular Templates is a clinical-stage company focused on the discovery and development of biologic therapeutic for cancer and other serious diseases. The company utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies (ETBs). The company is developing ETBs for various targets, including CD20, CD38, HER2, PD-L1, CTLA-4, SLAMF-7, and CD45. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of various myeloma. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.

MRC Global is a holding company. Through its subsidiaries, the company is a distributor of pipe, valves and fittings (PVF) and other infrastructure products and services to the energy industry. The company provides SKUs, including an array of PVF, oilfield supply, valve automation and modification, measurement, instrumentation and other general and specialty products. The company provides services such as product testing, manufacturer assessments, multiple daily deliveries, volume purchasing, inventory and zone store management and warehousing, technical support, training, delivery, order consolidation, product tagging and system interfaces, and engineering of control packages and valve inspection and repair.

Palo Alto Networks provides a platform that allows enterprises, service providers, and government entities to secure their organizations. The company's platform uses a traffic classification engine that identifies network traffic by application, user, and content and provides security across the network, endpoint, and cloud. The company's product, subscription, and support offerings include: firewall appliances and software; and Panorama, which is a centralized security management solution for global control of various firewall appliances and software deployed on an end-customer's network as well as in their instances in public or private cloud environments as a virtual appliance or a physical appliance.

PAR Technology, through its subsidiaries, operates in the following segments: Restaurant/Retail, which provides point-of-sale (POS) hardware, software and technical solutions to the restaurant and retail industries, including cloud-based, software-as-a-service Brink POS and on-premise POS PixelPoint solutions, POS hardware platforms, and installation, technical, and maintenance support services; and Government, which provides intelligence, surveillance, and reconnaissance solutions and mission systems support to the U.S. Department of Defense and other Federal agencies, including systems engineering and evaluation, space and satellite support services, and information systems support.

Precision Biosciences is a life sciences company. The company utilizes ARCUS in the development of its product candidates, which are designed to treat human diseases and create food and agricultural solutions. The company is developing product candidates in three areas: allogeneic chimeric antigen receptor T (CAR T) cell immunotherapy, in vivo gene correction, and food. The company's program, PBCAR0191, is an allogeneic CAR T cell therapy candidate targeting the tumor target CD19 and is being developed for the treatment of adult patients with non-Hodgkin lymphoma and relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Ryanair Holdings is a holding company. Through its subsidiaries, Co. operates an ultra-low cost, scheduled-passenger airline serving short-haul, point-to-point routes between Ireland, the U.K., Continental Europe, and Morocco. Co. offers over 2,000 scheduled short-haul flights per day serving approximately 210 airports throughout Europe, and flying approximately 1,600 routes. In addition, Co. provides various ancillary services and engages in other activities connected with its core air passenger service, including non-flight scheduled services, Internet-related services, and the in-flight sale of beverages, food, and merchandise.

Safeguard Scientifics provides capital and relevant services for the growth of businesses in healthcare, financial services and digital media. The company's existing group of partner companies consist principally of technology-driven businesses in healthcare, financial services and digital media that are capitalizing on the enabling technologies, including enhanced security and predictive analytics. The company typically deploys up to $25 million in a company.

SI-BONE is a medical device company. The company has a proprietary minimally invasive surgical implant system, which it calls iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company's iFuse system, which includes its implants and instruments, is designed to address the shortcomings of treatments, including open surgery, non-surgical management, and screw-based fusion procedures. The company's triangular iFuse implants cross the sacroiliac joint and provide joint stability. Also, the company's iFuse-3D is a patented titanium implant which combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design.

Skyline Champion is a producer of factory-built housing in the United States and Canada. The company serves as a solution provider across complementary and vertically integrated businesses including manufactured construction, company-owned retail locations, and transportation logistics services. The company produces a range of manufactured and modular homes under a variety of brand names and in a variety of floor plans and price ranges. While most of the homes the company builds are single-family, multi-section, ranch-style homes, it also builds two-story, single-section, and Cape Cod style homes as well as multi-family units such as town homes, apartments, duplexes, and triplexes.

The Bancorp is a financial holding company. The company's primary subsidiary is a wholly owned subsidiary bank, The Bancorp Bank (the Bank). The Bank has four primary lines of specialty lending: securities-backed lines of credit and insurance policy cash value-backed lines of credit, leasing (direct lease financing), small business loans and loans generated for sale into capital markets through commercial loan securitizations and other sales. Through the Bank, the company also provides banking services nationally, which include prepaid card accounts, private label banking, deposit accounts to investment advisors' customers, card payment and other payment processing.

Twist Bioscience is a synthetic biology company. The company is developing a disruptive DNA synthesis platform to industrialize the engineering of biology. The main of its platform is a proprietary technology that manufactures synthetic DNA by writing DNA on a silicon chip. The company has combined this technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create a technology platform. The company's offerings consists of two primary products that address different needs of its customers across a variety of applications: synthetic genes, oligonucleotide (oligo) pools, next generation sequencing tools and DNA libraries.

Vaxart is a clinical-stage biotechnology company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform. The company's oral vaccines are designed to generate immune responses that protect against infectious diseases. The company is developing prophylactic vaccine candidates that target a range of infectious diseases, including coronavirus disease 2019; norovirus, a widespread cause of acute gastro-intestinal enteritis; seasonal influenza; and respiratory syncytial virus, a common cause of respiratory tract infections. The company is also developing its therapeutic immune-oncology vaccine targeting cervical cancer and dysplasia caused by human papillomavirus.

Veracyte is a genomic diagnostics company. The company's products include the following: Afirma Genomic Sequencing Classifier and Xpression Atlas, which includes the Afirma GSC and Xpression Atlas; Percepta Bronchial Genomic Classifier, which improves lung cancer diagnosis by improving the performance of diagnostic bronchoscopies; Envisia Genomic Classifier, which improves diagnosis of idiopathic pulmonary fibrosis; and Prosigna Breast Cancer Prognostic Gene Signature Assay, which uses genomic technology to inform next steps for patients with early-stage breast cancer, based on the genomic make-up of their disease.

Waters is a holding company. Through its subsidiaries, the company is a specialty measurement company. The company primarily designs, manufactures, sells and services high performance liquid chromatography, ultra performance liquid chromatography and mass spectrometry technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans. In addition, the company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA? product line. The company is also a developer and supplier of software-based products that interface with its instruments, as well as other manufacturers' instruments.